|
1
|
Sudoh T, Minamino N, Kangawa K and Matsuo
H: C-type natriuretic peptide (CNP): A new member of natriuretic
peptide family identified in porcine brain. Biochem Biophys Res
Commun. 168:863–870. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Abassi Z, Karram T, Ellaham S, Winaver J
and Hoffman A: Implications of the natriuretic peptide system in
the pathogenesis of heart failure: Diagnostic and therapeutic
importance. Pharm Ther. 102:223–241. 2004. View Article : Google Scholar
|
|
3
|
Scotland RS, Ahluwalia A and Hobbs AJ:
C-type natriuretic peptide in vascular physiology and disease.
Pharm Ther. 105:85–93. 2005. View Article : Google Scholar
|
|
4
|
Del Ry S, Cabiati M, Vozzi F, Battolla B,
Caselli C, Forini F, Segnani C, Prescimone T, Giannessi D and
Mattii L: Expression of C-type natriuretic peptide and its receptor
NPR-B in cardiomyocytes. Peptides. 32:1713–1718. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Del Ry S, Maltinti M, Piacenti M, Passino
C, Emdin M and Giannessi D: Cardiac production of C-type
natriuretic peptide in heart failure. J Cardiovasc Med
(Hagerstown). 7:397–399. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kalra PR, Clague JR, Bolger AP, Anker SD,
Poole-Wilson PA, Struthers AD and Coats AJ: Myocardial production
of C-type natriuretic peptide in chronic heart failure.
Circulation. 107:571–573. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Moyes AJ, Chu SM, Aubdool AA, Dukinfield
MS, Margulies KB, Bedi KC, Hodivala-Dilke K, Baliga RS and Hobbs
AJ: C-type natriuretic peptide co-ordinates cardiac structure and
function. Eur Heart J. (pii): ehz093Mar 21–2019.(Epub ahead of
print). PubMed/NCBI
|
|
8
|
Calvieri C, Rubattu S and Volpe M:
Molecular mechanisms underlying cardiac anti-hypertrophic and
antifibrotic effects of natriuretic peptides. J Mol Med (Berl).
90:5–13. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang Y, de Waard MC, Sterner-Kock A,
Stepan H, Schultheiss HP, Duncker DJ and Walther T:
Cardiomyocyte-restricted over-expression of C-type natriuretic
peptide prevents cardiac hypertrophy induced by myocardial
infarction in mice. Eur J Heart Fail. 9:548–557. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Soeki T, Kishimoto I, Okumura H, Tokudome
T, Horio T, Mori K and Kangawa K: C-type natriuretic peptide, a
novel antifibrotic and antihypertrophic agent, prevents cardiac
remodeling after myocardial infarction. J Am Coll Cardiol.
45:608–616. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dhein S: Gap junction channels in the
cardiovascular system: Pharmacological and physiological
modulation. Trends Pharmacol Sci. 19:229–241. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Davis LM, Kanter HL, Beyer EC and Saffitz
JE: Distinct gap junction protein phenotypes in cardiac tissues
with disparate conduction properties. J Am Coll Cardiol.
24:1124–1132. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Davis LM, Rodefeld ME, Green K, Beyer EC
and Saffitz JE: Gap junction protein phenotypes of the human heart
and conduction system. J Cardiovasc Electrophysiol. 6:813–822.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Severs NJ, Coppen SR, Dupont E, Yeh HI, Ko
YS and Matsushita T: Gap junction alterations in human cardiac
disease. Cardiovasc Res. 62:368–377. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tanaka H, Matsuyama TA and Takamatsu T:
Towards an integrated understanding of cardiac
arrhythmogenesis-growing roles of experimental pathology. Pathol
Int. 67:8–16. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kim S and Iwao H: Molecular and cellular
mechanisms of angiotensin II-mediated cardiovascular and renal
diseases. Pharmacol Rev. 52:11–34. 2000.PubMed/NCBI
|
|
17
|
Zhang B, Cui X, Jin HH, Hong L, Liu X, Li
X, Zhang QG and Liu LP: Ginsenoside Re prevents angiotensin
II-induced gap-junction remodeling by activation of PPARγ in
isolated beating rat atria. Life Sci. 190:36–45. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
National Research Council (US) Committee
for the Update of the Guide for the Care and Use of Laboratory
Animals: Guide for the Care and Use of Laboratory Animals8th.
National Academies Press (US); Washington, DC: 2011
|
|
19
|
Qi H, Liu Y, Li S, Chen Y, Li L, Cao Y, E
M, Shi P, Song C, Li B and Sun H: Activation of AMPK attenuated
cardiac fibrosis by inhibiting CDK2 via p21/p27 and miR-29 family
pathways in ratsnd. Mol Ther Nucleic Acids. 8:277–290. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu X, Zhang Y, Hong L, Han CJ, Zhang B,
Zhou S, Wu CZ, Liu LP and Cui X: Gallic acid increases atrial
natriuretic peptide secretion and mechanical dynamics through
activation of PKC. Life Sci. 181:45–52. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gu X, Fang T, Kang P, Hu J, Yu Y, Li Z,
Cheng X and Gao Q: Effect of ALDH2 on high glucose-induced cardiac
fibroblast oxidative stress, apoptosis, and fibrosis. Oxid Med Cell
Longev. Oct 9–2017.(Epub ahead of print). View Article : Google Scholar
|
|
22
|
Horio T, Tokudome T, Maki T, Yoshihara F,
Suga S, Nishikimi T, Kojima M, Kawano Y and Kangawa K: Gene
expression, secretion, and autocrine action of C-type natriuretic
peptide in cultured adult rat cardiac fibroblasts. Endocrinology.
144:2279–2284. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Del Ry S: C-type natriuretic peptide: A
new cardiac mediator. Peptides. 40:93–98. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wenzel S, Taimor G, Piper HM and Schlüter
KD: Redox-sensitive intermediates mediate angiotensin II-induced
p38 MAP kinase activation, AP-1bindingactivity, and TGF-beta
expression in adult ventricular cardiomyocytes. FASEBJ.
15:2291–2293. 2001. View Article : Google Scholar
|
|
25
|
Izumiya Y, Araki S, Usuku H, Rokutanda T,
Hanatani S and Ogawa H: Chronic C-type natriuretic peptide infusion
attenuates angiotensin II-induced myocardial superoxide production
and cardiac remodeling. Int J Vasc Med. 2012:2460582012.PubMed/NCBI
|
|
26
|
Ichiki T, Boerrigter G, Huntley BK,
Sangaralingham SJ, McKie PM, Harty GJ, Harders GE and Burnett JC
Jr: Differential expression of the pro-natriuretic peptide
convertases corin and furin in experimental heart failure and
atrial fibrosis. Am J Physiol RegulIntegr Comp Physiol.
304:R102–R109. 2013. View Article : Google Scholar
|
|
27
|
Mishra R, Cool BL, Laderoute KR, Foretz M,
Viollet B and Simonson MS: AMP-activated protein kinase inhibits
transforming growth factor-beta-induced Smad3-dependent
transcription and myofibroblast transdifferentiation. J Biol Chem.
283:10461–10469. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hernandez JS, Barreto-Torres G, Kuznetsov
AV, Khuchua Z and Javadov S: Crosstalk between AMPK activation and
angiotensin II-induced hypertrophy in cardiomyocytes: The role of
mitochondria. J Cell Mol Med. 18:709–720. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Fujita K, Maeda N, Sonoda M, Ohashi K,
Hibuse T, Nishizawa H, Nishida M, Hiuge A, Kurata A, Kihara S, et
al: Adiponectin protects against angiotensin II-induced cardiac
fibrosis through activation of PPAR-alpha. Arterioscler Thromb Vasc
Biol. 28:863–870. 2008. View Article : Google Scholar : PubMed/NCBI
|
